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CASE REPORT
Fig. 1. A black discoloration with a hairy appearance on the 
dorsal surface of the tongue.
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Erlotinib is a tyrosine kinase inhibitor that acts on the 
epidermal growth factor receptor (EGFR). There have been 
many reports of the mucocutaneous side effects related to 
several EGFR inhibitors (EGFRIs). However, no case of black 
hairy tongue (BHT) associated with EGFRI has been reported. 
Herein, we report the first case of erlotinib-induced BHT in 
a 61-year-old man with advanced lung cancer. Considering 
recent use of EGFRIs worldwide, dermatologists should 
recognize the possible occurrence of BHT associated with 
EGFRIs such as erlotinib. (Ann Dermatol 23(4) 526∼528, 
2011)
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INTRODUCTION
Erlotinib is a tyrosine kinase inhibitor that acts on the 
epidermal growth factor receptor (EGFR) and has been 
approved to treat advanced non-small cell lung cancer 
and pancreatic cancer
1. There have been many reports of 
the cutaneous or mucosal side effects related to several 
EGFR inhibitors (EGFRIs)
2. However, no case of black 
hairy tongue (BHT) associated with a EGFRI has been 
reported. Herein, we report the first case of erlotinib- 
induced BHT in an elderly man with advanced lung 
cancer.
CASE REPORT
A 61-year-old man presented with an asymptomatic black 
discoloration of the tongue that he noticed 1 month 
earlier. He was diagnosed with advanced lung cancer 
(squamous cell carcinoma, T4N2M1) 4 months before and 
had received three cycles of chemotherapy once per 
month. Due to a lack of efficacy, he began to take 
erlotinib 100 mg daily 4 weeks after the last chemo-
therapy. Four days later, he noticed black discoloration 
and hairy changes on his tongue. A physical examination 
of the lesion revealed a black discoloration with hairy 
elevation of the filiform papillae on the dorsal surface of Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer
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the tongue (Fig. 1). Otherwise, his physical findings were 
unremarkable. A KOH examination and fungal culture 
from the tongue surface were negative. He refused a skin 
biopsy and further evaluation of his tongue lesion. A 
diagnosis of BHT was made based on the clinical findings, 
and erlotinib was subsequently discontinued. However, 
other medications such as oxycodone, metoclopramide, 
ranitidine, acetylcysteine, and magnesium oxide were 
continued to control a variety of complications from lung 
cancer. His tongue lesion completely resolved 5 weeks 
after withdrawal of erlotinib.
DISCUSSION
BHT, or lingua villosa nigra, is an unusual, benign, and 
typically asymptomatic disorder characterized by abnor-
mal elongation and hypertrophy of the filiform papillae of 
the tongue
3. Overgrowth of the filiform papillae caused by 
defective desquamation of the epithelium results in a hairy 
appearance and black to brownish discoloration, com-
monly on the posterior dorsal surface of the tongue
4. 
Although the definite pathogenesis of BHT has remained 
uncertain, many factors are linked to BHT and one of 
them is antibiotics such as penicillin, erythromycin, tetra-
cycline, doxycycline, and linezolid. Additionally, other 
medications, including lansoprazole, olanzapine, and bis-
muth, can precipitate BHT
3.
We concluded that the diagnosis of our patient was 
drug-induced BHT, and that erlotinib was the probable 
culprit drug based on the expanded Naranjo adverse drug 
reaction probability scale proposed by Thompson and 
Kessler
3. The patient’s total score was at least 5 points 
according to the onset of BHT temporally related to 
erlotinib administration (＋2), temporally related reso-
lution of BHT after drug withdrawal (＋1), and no alter-
native causes other than erlotinib (＋2). The occurrence of 
BHT was temporally related to treatment with erlotinib, 
and the lesion improved after discontinuation. No cases of 
BHT have been associated with EGFRIs treatment despite 
their various mucocutaneous adverse events, including 
acneiform eruption, xerosis, paronychia, trichomegaly, 
and mucosal aphthae
2.
Psoriasis is usually induced by tumor necrosis factor 
(TNF)-α and regressed by TNF-α antagonists
5,6. In same 
manner, BHT may be aggravated by EGF and EGFR. 
Iwasaki et al.
7 reported that EGF and EGFR are expressed 
in the lingual mucosa during the morphogenesis of 
filiform papillae in rats. They suggested that EGF might 
influence keratin expression in the lingual epithelium. 
Furthermore, EGF may regulate proliferation and differen-
tiation of cultured epithelial cells derived from the tongue 
of adult mice
8. BHT results from disturbing epithelial 
desquamation on the filiform papillae of the tongue
4, 
whereas EGFRIs promote desquamation of the skin as a 
side effect
2. Theoretically, EGFRIs may be helpful to 
alleviate a hairy appearance of BHT. Therefore, BHT 
associated with erlotinib may be a paradoxical pheno-
menon similar to the worsening of psoriasis during 
treatment with TNF-α antagonists
9. Although we cannot 
clearly explain how erlotinib induces BHT, we presume 
that erlotinib may interrupt the inherent role of EGF and 
EGFR in the lingual epithelium.
In summary, our patient met the requirement for a 
diagnosis of drug-induced BHT, which was related to 
erlotinib administration. Because the precise mechanism 
of EGFR and its inhibitor in the pathogenesis of BHT is 
unknown, further study is warranted to understand this 
paradoxical phenomenon. Considering recent use of 
EGFRIs worldwide, dermatologists should recognize the 
possible occurrence of BHT associated with EGFRIs such 
as erlotinib.
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